Daphne Zohar

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐨𝐮𝐫: BiotechTV visited the new offices of @seaporttx.bsky.social today and was given a tour by Founder & CEO @daphnezohar.bsky.social

Biotech CEO Sisterhood: As CEO, Sophie Kornowski sold Boston Pharmaceuticals to GSK earlier this year for up to $2 billion. She shares her thoughts on the biopharma business and leadership Interviewed by Sisterhood editorial board member Daphne Zohar, Sophie Kornowski shares her keys to creating great assets, commercialization, partnerships, and, ultimately, executing a successful deal ...

For @biotechtv.bsky.social's Biotech CEO Sisterhood series, our CEO @daphnezohar.bsky.social spoke to Sophie Kornowski on her journey leading Boston Pharmaceuticals to a $2B deal w/ GSK. Check this out for insights from both leaders on dealmaking, leadership strategies & mentorship: bit.ly/4m55kzG

Pleased to announce the first patient has been dosed in our Ph2b BUOY-1 study of GlyphAllo™ (SPT-300) in #MDD w/ or w/o anxious distress, an important milestone for Seaport’s pipeline that brings us closer to a potential new treatment for patients w/ MDD: bit.ly/3Uhn3YB

#BiotechHangout Eric Schmidt, Brad Loncar, Tim Opler, Tess Cameron on M&A: $MRK/$VRNA, $ABBV/Capstan, biotech takeouts, M&A wave, pharma’s $150B in LOE, plus Trump’s BBB/tariffs, $XBI & MFN, FDA’s CRL disclosures, $CAPR, $KALV, $PROK, obesity trends, $RARE/$MREO, $ABBV/Ichnos: bit.ly/3TuICVp

The Seaport crew kicked off summer with a fun gathering! Great opportunity to connect out of the office, strengthening our mission to develop life-changing medicines for #neuropsychiatric disorders. Looking forward to more moments together and progress towards transforming lives!

As #MentalHealthMonth closes, we welcomed a @namicommunicate.bsky.social patient representative to share his journey w/ mental health conditions. His story inspires our work at Seaport to help those struggling & develop new medicines for #depression & #anxiety. More: www.nami.org

#BiotechHangout: Chris Garabedian, Josh Schimmer, Nina Kjellson, Mike Yee, Tim Opler on market sentiment – where is the M&A?, FDA/CBER, wind downs vs reverse mergers, policy: #MAHA & COVID vaccine, $REGN/23andMe, data: $RCKT, psychedelics, $PRTA, $SPRO/$GSK, $GILD, $SMMT, #ASCO & more bit.ly/4dCFzDT

Man, woman shot and killed in front of Capital Jewish Museum in DC A man and woman were shot and killed in front of the Capital Jewish Museum in Northwest D.C. Wednesday evening. The shooting took place in the area of 3rd and F streets in Northwest — in front of the ...

Two people were shot and killed outside a Jewish LGBTQ event in D.C.

This #MentalHealthMonth, we joined @namicommunicate.bsky.social's annual #NAMIWalks to combat stigma & promote mental health awareness. We stand with those affected by mental illness & are dedicated to developing new medicines for #depression & #anxiety. More about NAMI www.nami.org

#BiotechHangout: Sam Fazeli, John Maraganore, Nina Kjellson, Matt Gline on MFN: 30-day ultimatum, 180 days negotiation, reimportation, ex-US prices, DTC, Roche, $SNY, plus: budget reconciliation, IRA, $RXRX, Galapagos, $CTMX, $GSK buys Boston, $GSK/iTeos, $NVO CEO, RNA deals: bit.ly/3S3vhTh

Linked in and X

Seems like Bluesky is losing momentum? Wouldn’t mind having one less place to check/post. Curious to hear from others

Important provisions added to reconciliation bills would be positive for bio if passed:

ORPHAN Cures Act included, amend IRA

PBM reforms delinking compensation from list price, increasing transparency & banning spread pricing in Medicaid

Tax fix to allow for immediate deduction of R&D costs

Cantor has put out some really interesting notes lately. Dueling takes from Eric Schmidt & Josh Schimmer on short selling last week and then this week a thoughtful critique of issues that are ailing our industry. Link below:
cantor2.bluematrix.com/sellside/Ema...

#BiotechHangout: Eric Schmidt, Sam Fazeli, Adam Feuerstein, Peter Kolchinsky on $XBI, market & macro trends, latest from FDA/Washington, Q1 earnings trends: tariffs, M&A & drug launches, data: $SMMT/Akeso & #AUA2025 & #AACR25 recap ($PFE, $JNJ, $BNTX, $CGON, China ADCs): twitter.com/i/spaces/1gq...

#Depression & #anxiety are among the most common & disabling #mentalhealth conditions. This #MentalHealthAwarenessMonth we're spotlighting our commitment to developing better medicines & reducing the stigma for those dealing w/these conditions. Learn more: www.seaporttx.com

Exclusive: In conversation with FDA Commissioner Dr. Marty Makary. In our wide-ranging Q&A, Dr. Makary outlines his vision, addresses low morale, asserts his independence, explains his stance on Novavax, and says "no" to an agency reorganization.

“When Secretary Kennedy offers a suggestion to me, he always adds, “You decide for yourself.” So, yes, there is independence.” New interview with Marty Makary sheds more light on re-org (no plans), PDUFA dates, morale and his independence from RFK insidemedicine.substack.com/p/exclusive-...

#BiotechHangout: Daphne Zohar, Josh Schimmer, Tim Opler, John Maraganore, Paul Matteis on macroenvironment, $XBI, $SWTX $MRCG takeout rumors, policy: (FDA, tariffs), data: ($BMY, $QURE, #AUA25: $JNJ/$CGON), Trump vs. Harvard, buyside & short-selling, CEO survival tips: x.com/biotechch/st...

We're at #SOBP2025 to present new preclinical data on SPT-320, a novel oral prodrug of agomelatine. SPT-320 increased lymphatic transport >50% compared to <1% agomelatine alone & increased plasma exposure >10-fold. SPT-320 progressing into clinic for #GAD. bit.ly/4ixtOzs

X | Daphne Zohar Takeaways from this new Marty Makary M.D., M.P.H. interview on Megyn Kelly: -“Why does it take 10 years to bring a drug to market in US? People are dying. Our # 1 goal is delivering cures, meaningfu...

Makary interview: “Why does it take 10 years to bring a drug to market in US? People are dying. Our # 1 goal is delivering cures, meaningful treatments, healthier food” 1 randomized controlled trial & then intense post marketing surveillance (link for full text):
www.linkedin.com/posts/daphne...

Insider close to administration: Elon’s DOGE work almost done. Lutnick & Navarro losing influence & Bessent gaining. Most interesting: “If Secretary of HHS makes it through the year I’ll be shocked.” Oz important. Last night’s EO opportunity “pill penalty.” Sounds like they’re coming after CVS/PBMs

Thank you 🙏

Congrats @daphnezohar.bsky.social, named to @statnews.com #STATUSList, "the ultimate list of leaders in health, medicine, & science," for founding Seaport & raising $325M. “That’s big & her influence on the biotech field extends beyond that” & cofounding Karuna & PureTech bit.ly/4coOF6B

Preserving and Modernizing the FDA — No Patient Left Behind

www.nopatientleftbehind.org/preserving-t...

Here’s a letter that a group of biotech CEOs/investors have addressed to Sen Cassidy, Chair of Senate HELP committee which describes issues biotech companies are experiencing wrt @US_FDA cuts & offers specific and actionable solutions.

Please sign & share

nopatientleftbehind.org/preserving-the…

Seaport aims to develop better treatments for depression & anxiety. This commitment comes from our exceptional team, all rowing in the same direction to deliver new drugs to make the lives of patients better. What inspires us daily? Hear from our team!

Should be helpful for US biotech. National Security Commission on Emerging Biotechnology Urges Swift Action to Protect U.S. National Security $XBI $BBC biotech.senate.gov

It’s been a year!!